Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum
The cause of degeneration of nigrostriatal dopamine (DA) neurons in idiopathic Parkinson's
disease (PD) is still unknown. Intraneuronally, DA is largely confined to synaptic vesicles …
disease (PD) is still unknown. Intraneuronally, DA is largely confined to synaptic vesicles …
Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
C Pifl, H Drobny, H Reither, O Hornykiewicz… - Molecular …, 1995 - ASPET
The effects of amphetamine and cocaine were studied in [3H]-dopamine-loaded and
superfused COS-7 cells transfected with either the cDNA of the plasmalemmal dopamine …
superfused COS-7 cells transfected with either the cDNA of the plasmalemmal dopamine …
Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis: effects on renal hemodynamics and atrial natriuretic factor
K Lenz, H Hörtnagl, W Druml, H Reither, R Schmid… - Gastroenterology, 1991 - Elsevier
In 11 patients with decompensated cirrhosis and deteriorating renal function, the effect of
the vasoconstrictor substance 8-ornithin vasopressin (ornipressin; POR 8; Sandoz, Basel, …
the vasoconstrictor substance 8-ornithin vasopressin (ornipressin; POR 8; Sandoz, Basel, …
The profile of mephedrone on human monoamine transporters differs from 3, 4-methylenedioxymethamphetamine primarily by lower potency at the vesicular …
C Pifl, H Reither, O Hornykiewicz - European journal of pharmacology, 2015 - Elsevier
Mephedrone (4-methylmethcathinone, MMC) and 3,4-methylenedioxymethamphetamine (MDMA)
are constituents of popular party drugs with psychoactive effects. Structurally they are …
are constituents of popular party drugs with psychoactive effects. Structurally they are …
[HTML][HTML] Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson
C Pifl, H Reither, J Attems, L Zecca - npj Parkinson's Disease, 2023 - nature.com
Incidental Lewy body disease (ILBD) is a neuropathological diagnosis of brains with Lewy
bodies without clinical neuropsychiatric symptoms. Dopaminergic deficits suggest a …
bodies without clinical neuropsychiatric symptoms. Dopaminergic deficits suggest a …
Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner
C Pifl, A Wolf, P Rebernik, H Reither, ML Berger - Neuropharmacology, 2009 - Elsevier
The dopamine transporter (DAT), a membrane protein specifically expressed by dopaminergic
neurons and mediating the action of psychostimulants and dopaminergic neurotoxins, is …
neurons and mediating the action of psychostimulants and dopaminergic neurotoxins, is …
[HTML][HTML] The psychostimulant (±)-cis-4, 4′-dimethylaminorex (4, 4′-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters
(±)-cis-4,4′-Dimethylaminorex (4,4′-DMAR) is a new psychoactive substance (NPS) that
has been associated with 31 fatalities and other adverse events in Europe between June …
has been associated with 31 fatalities and other adverse events in Europe between June …
α-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter
C Pifl, M Khorchide, A Kattinger, H Reither, J Hardy… - Neuroscience …, 2004 - Elsevier
The established or potentially toxic agents implicated in the nigral cell death in Parkinson's
disease, dopamine, 1-methyl-4-phenylpyridinium (MPP + ), iron, and manganese, were …
disease, dopamine, 1-methyl-4-phenylpyridinium (MPP + ), iron, and manganese, were …
Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters
C Pifl, G Nagy, S Berényi, A Kattinger, H Reither… - … of Pharmacology and …, 2005 - ASPET
Ecstasy samples often contain byproducts of the illegal, uncontrolled synthesis of N-methyl-3,4-methylenedioxy-amphetamine
or 3,4-methylenedioxymethamphetamine (MDMA). MDMA …
or 3,4-methylenedioxymethamphetamine (MDMA). MDMA …
The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine
C Sommerauer, P Rebernik, H Reither, C Nanoff… - …, 2012 - Elsevier
Amantadine is an established antiparkinsonian drug with a still unclear molecular site of
action. In vivo studies on rodents, in vitro studies on tissue of rodents as well as binding studies …
action. In vivo studies on rodents, in vitro studies on tissue of rodents as well as binding studies …